Idiopathic pulmonary fibrosis (IPF) is an intractable interstitial lung disease characterized by fibroblastic foci, remodeling and obliteration of alveoli, and a median survival of 3 to 4 years. The only definitive treatment is lung transplantation, an intervention hampered by low availability of donor organs, and severe surgical and immunological complications. Innovative approaches are therefore urgently needed. We identified three major challenges towards improving the prognosis of IPF, and propose to address these challenges in the three research hubs of our consortium: (1) Cell sources should be established to study pathogenesis of IPF and to eventually prevent or reverse fibrosis. In Hub 1, we propose directed differentiation of human pluripotent stem cells (hPSCs) into lung tissue to investigate pathogenesis and establish platforms for drug discovery. (2) Cell removal/delivery methods are needed to either replace irreversibly damaged lung tissue, or the cells that carry pathogenesis of IPF. In Hub 2, we will develop the necessary bioengineering modalities that will take advantage of directed differentiation of hPSCs into lung tissue. (3) The field requires a large animal model for the validation of pathogenetic mechanisms and preclinical validation of novel therapeutic modalities for IPF developed by the first two research hubs. We therefore propose to establish a miniature swine model for IPF to validate pathogenetic mechanisms discovered in Hub1, and cellular replacement approaches developed in Hub 2. The overarching goal of this proposal is to gain desperately needed insight into the pathogenesis of IPF (Hub 1) and to use these insights to inform the development of novel therapeutic approaches for IPF (Hub 2). As IPF is currently an untreatable disease, it is not possible to predict which approaches will be beneficial, and the therapy may be dictated by disease stage. Pharmacological approaches may target the fibrotic process itself, or pathways emanating from epithelial cells that initiate this process and would likely be useful in early stage disease or in patients that are genetically predisposed. Regenerative approaches could consist of cellular therapies, in particular targeting ATII cells, most likely early in disease or in patients predisposed to IPF, but may extend to transplantation of recellularized lung scaffolds in end-stage disease. Both types of regenerative approaches will require bioengineering technologies that will be developed Hub 2 and informed by a deeper understanding of IPF pathogenesis achieved in Hub 1. Ultimately, verification of disease mechanism and preclinical testing of therapeutic approaches requires a large animal model, which is the focus of Hub 3.

Public Health Relevance

Idiopathic pulmonary fibrosis is an intractable and ill-understood lung disease with a median survival of 3 to 4 years. There is currently no curative treatment for this disease, except for lung transplantation, an intervention hampered by low availability of donor organs, and severe surgical, medical and immunological complications. We propose an interdisciplinary approach designed to gain desperately needed insight into this disease and develop innovative therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01HL134760-01
Application #
9221070
Study Section
Special Emphasis Panel (ZHL1-CSR-O (S1))
Program Officer
Lin, Sara
Project Start
2016-09-20
Project End
2023-05-31
Budget Start
2016-09-20
Budget End
2017-05-31
Support Year
1
Fiscal Year
2016
Total Cost
$954,800
Indirect Cost
$354,810
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Guenthart, Brandon A; O'Neill, John D; Kim, Jinho et al. (2018) Cell replacement in human lung bioengineering. J Heart Lung Transplant :
Ronaldson-Bouchard, Kacey; Vunjak-Novakovic, Gordana (2018) Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. Cell Stem Cell 22:310-324
Kim, Jinho; Guenthart, Brandon; O'Neill, John D et al. (2017) Controlled delivery and minimally invasive imaging of stem cells in the lung. Sci Rep 7:13082
Chen, Ya-Wen; Huang, Sarah Xuelian; de Carvalho, Ana Luisa Rodrigues Toste et al. (2017) A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 19:542-549
Dorrello, N Valerio; Guenthart, Brandon A; O'Neill, John D et al. (2017) Functional vascularized lung grafts for lung bioengineering. Sci Adv 3:e1700521